Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07649941
PHASE1

A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the Blood

Sponsor: Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

The main objective of this trial is to investigate the effect of a moderate CYP 3A inducer bosentan on the pharmacokinetics of zongertinib.

Official title: The Effect of Multiple Oral Doses of Bosentan on the Single Oral Dose Pharmacokinetics of Zongertinib in Healthy Male Subjects (an Open-label, Two-treatment, Two-period Fixed Sequence Trial)

Key Details

Gender

MALE

Age Range

25 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2026-06-22

Completion Date

2026-08-19

Last Updated

2026-06-16

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Zongertinib

Zongertinib

DRUG

Bosentan

Bosentan

Locations (1)

Humanpharmakologisches Zentrum Biberach

Biberach, Germany